AI-generated summary
The authors report a triple-blind, randomized, placebo-controlled trial of transcranial photobiomodulation in 40 people with Parkinson's disease, comparing active light (635 nm plus 810 nm) with sham over 12 weeks. They found no significant difference in total motor scores between groups, with some sub-score changes reported in each arm and no safety concerns beyond minor dizziness. As a post-hoc analysis, the subgroup findings are exploratory and the authors attribute the lack of overall difference to a possible placebo effect.
- Participants
- 40
- Who or what was studied
- Adults with idiopathic Parkinson's disease
- Wavelengths
- 635, 810 nm
- Limits stated in the abstract
- The motor-outcome findings come from a post-hoc analysis, and the overall total score showed no significant difference between active and sham groups.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
Emerging evidence is increasingly supporting the use of transcranial photobiomodulation (tPBM) to improve symptoms of neurodegenerative diseases, including Parkinson's disease (PD). The objective of this study was to analyse the safety and efficacy of tPBM for PD motor symptoms. The study was a triple blind, randomized placebo-controlled trial with 40 idiopathic PD patients receiving either active tPBM (635 nm plus 810 nm LEDs) or sham tPBM for 24 min per day (56.88J), six days per week, for 12 weeks. The primary outcome measures were treatment safety and a 37-item MDS-UPDRS-III (motor domain) assessed at baseline and 12 weeks. Individual MDS-UPDRS-III items were clustered into sub-score domains (facial, upper-limb, lower-limb, gait, and tremor). The treatment produced no safety concerns or adverse events, apart from occasional temporary and minor dizziness. There was no significant difference in total MDS-UPDRS-III scores between groups, presumably due to the placebo effect. Additional analyses demonstrated that facial and lower-limb sub-scores significantly improved with active treatment, while gait and lower-limb sub-scores significantly improved with sham treatment. Approximately 70% of participants responded to active treatment (≥5 decrease in MDS-UPDRS-III score) and improved in all sub-scores, while sham responders improved in lower-limb sub-scores only. tPBM appears to be a safe treatment and improved several PD motor symptoms in patients that responded to treatment. tPBM is proving to be increasingly attractive as a possible non-pharmaceutical adjunct therapy.
Abstract reproduced under the CC BY license. Source: PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 635 nm, 810 nm
- Total energy
- 56.88J
How to read a single study: what to check before relying on this kind of research.
Terms in this paper: Transcranial photobiomodulation, Photobiomodulation, Placebo-controlled, Sham, Primary outcome, Placebo effect. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.